Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

NCT03013335 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT03013335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03013335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2016
Completion date
June 30, 2021
Enrollment
730 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma